Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 85
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT03075826 | A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms | ||
| NCT00144430 | Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children | ||
| NCT04411030 | A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam | ||
| NCT00032773 | Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD | ||
| NCT00881166 | Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors | ||
| NCT05245682 | Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer | ||
| NCT00571662 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | ||
| NCT02197676 | A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response | ||
| NCT00443976 | Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma | ||
| NCT05360160 | A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | ||
| NCT04013880 | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | ||
| NCT00005874 | Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas | ||
| NCT05007873 | ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase | ||
| NCT00005873 | Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | ||
| NCT00005876 | Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery | ||
| NCT00496873 | Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan | ||
| NCT00005872 | Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer | ||
| NCT00506922 | Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT | ||
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | ||
| NCT00254163 | Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients | ||
| NCT03813186 | Effect of Food on Blood Levels of ASTX727 | ||
| NCT00042016 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | ||
| NCT06297629 | A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation | ||
| NCT04155580 | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | ||
| NCT02348489 | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | ||
| NCT00005869 | Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer | ||
| NCT05456269 | A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS | ||
| NCT01652144 | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma | ||
| NCT02998567 | Combination Study of Guadecitabine/ASTX727 and Pembrolizumab | ||
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma | ||
| NCT01685268 | A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | ||
| NCT01261312 | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | ||
| NCT01145989 | A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma | ||
| NCT00541034 | Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | ||
| NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | ||
| NCT00131313 | Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. | ||
| NCT00113113 | Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction | ||
| NCT00894894 | Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies | ||
| NCT00005870 | Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas | ||
| NCT00005875 | Nitrocamptothecin in Treating Patients With Metastatic Melanoma | ||
| NCT05082259 | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab | ||
| NCT00878423 | Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors | ||
| NCT04250246 | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 | ||
| NCT06802146 | Early Intervention in High Risk CCUS | ||
| NCT03922555 | ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas | ||
| NCT04655755 | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | ||
| NCT02920008 | Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | ||
| NCT00043381 | Decitabine Versus Supportive Care in Adults With Advanced-stage MDS | ||
| NCT01357395 | A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer | ||
| NCT02901899 | Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
